ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 979

Stopping Medicines for Inactive Juvenile Idiopathic Arthritis: What Do Patients and Families Consider?

Daniel B. Horton1,2, Jomaira Salas3, Aleksandra Wec4, Timothy Beukelman5, Alexis Boneparth6, Jaime Guzman7, Ky Haverkamp8, Melanie Kohlheim9, Melissa L. Mannion5, Nandini Moorthy1, Elizabeth Stringer10, Lori Tucker7, Sarah Ringold11 and Marsha Rosenthal2, 1Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, 3Department of Sociology, Rutgers, the State University of New Jersey, New Brunswick, NJ, 4Mathematica Policy Research, Princeton, NJ, 5Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 6Pediatrics, Columbia University Medical Center, New York, NY, 7Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 8Family Medicine, University of Washington School of Medicine, Seattle, WA, 9Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, 10IWK Health Centre, Dalhousie University, Halifax, NS, Canada, 11Pediatrics, Seattle Children's Hospital, Seattle, WA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease-modifying antirheumatic drugs, doctor-patient relationship, juvenile idiopathic arthritis (JIA), patient questionnaires and qualitative

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: 3S115 ACR/ARHP Abstract: Pediatric Rheum (976–981)

Session Type: ACR/ARHP Combined Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Prior research has focused on factors important to clinicians in decisions about withdrawing JIA therapy. Based on recent interviews with patients and caregivers about stopping JIA therapy, we conducted an online survey to study the trade-offs patients and caregivers consider when deciding to stop treatments.

Methods: From June 2017 to February 2018, we conducted an anonymous online survey in English and Spanish using REDCap software. We recruited volunteer participants via social media, email, and flyers in pediatric rheumatology clinics in the US and Canada. Eligible participants were (1) adolescents with JIA (13-17y), (2) adults with JIA (≥18y), or (3) caregivers of children with JIA. Survey questions focused on factors that might influence decisions about stopping JIA treatment. Questions were based on findings from prior interviews and refined via pilot testing. We analyzed responses using descriptive statistics.

Results: 1456 individuals opened the survey and 839 (58%) completed it, including 782 eligible participants (40 adolescents, 120 young adults, and 622 caregivers).A majority of the participants were from the US, had a history of severe JIA flares, and used systemic anti-rheumatic medicines. Overall, adult patients were more likely than caregivers or adolescents to report having more severe disease and more complications from JIA and treatment. Among all groups, damage from JIA was the most highly ranked consideration in deciding whether to stop treatment (Table). Those with prior disease complications (e.g., severe flare, disability) were more likely to prioritize risk of flares in decision-making and generally less concerned about future drug effects (Figure). In contrast, those with prior treatment complications were more likely to prioritize risk of drug side effects (Figure). Trust in physicians was especially important for caregivers and adolescents (Table). Those reporting greater trust in physicians were more willing to accept physicians’ recommendations to continue or stop treatment (P<0.01).

Conclusion: Among survey respondents, JIA-related damage was the top consideration in deciding whether to stop treatments for well-controlled JIA. Past complications from JIA or from treatment influenced the ranking of other considerations. Greater trust in physicians increased willingness to accept physicians’ recommendations. These findings can help inform shared decision-making when considering whether to stop medicines for well-controlled JIA.


Disclosure: D. B. Horton, Bristol-Myers Squibb, 2; J. Salas, None; A. Wec, None; T. Beukelman, UCB, Inc., 5,Novartis, 5,Sobi, 5,Bristol-Myers Squibb, 5; A. Boneparth, None; J. Guzman, None; K. Haverkamp, None; M. Kohlheim, None; M. L. Mannion, None; N. Moorthy, None; E. Stringer, None; L. Tucker, None; S. Ringold, None; M. Rosenthal, None.

To cite this abstract in AMA style:

Horton DB, Salas J, Wec A, Beukelman T, Boneparth A, Guzman J, Haverkamp K, Kohlheim M, Mannion ML, Moorthy N, Stringer E, Tucker L, Ringold S, Rosenthal M. Stopping Medicines for Inactive Juvenile Idiopathic Arthritis: What Do Patients and Families Consider? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/stopping-medicines-for-inactive-juvenile-idiopathic-arthritis-what-do-patients-and-families-consider/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stopping-medicines-for-inactive-juvenile-idiopathic-arthritis-what-do-patients-and-families-consider/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences